Antisense Therapeutics is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development.

The Company Vision: To serve the needs of our patients and stakeholders to the best of our combined
abilities.

The Company Mission: To bring life changing innovative medicines to patients in need and to add value for
all stakeholders through actively exercising our beliefs of honesty, integrity and collaboration.

The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne Muscular Dystrophy (DMD) patients and recently reported highly promising Phase II trial results.  ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.

Latest News

ATL1102 for DMD Clinical Trial Application Submitted in Europe

New Muscle Disease Indication for ATL1102 – Limb Girdle Muscular Dystrophy R2

Presentation at 2nd Annual Oligonucleotide for CNS Summit

Investor Presentation

Quarterly Activities/Appendix 4C

Menu